Basic Information
| LncRNA/CircRNA Name | FEZF1-AS1 |
| Synonyms | NR_036484 |
| Region | GRCh38_7:122303658-122310077 |
| Ensemble | ENSG00000230316 |
| Refseq | NR_036484 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | paclitaxe | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot etc |
| Sample | PC tissues,cell lines (DU145 and LNCaP) |
| Expression Pattern | up-regulated |
| Function Description | In this study, the expression of FEZF1-AS1 and ITGB8 was upregulated, whereas the expression of miR-25-3p was downregulated in PC tumor tissues and PC/PTX cells. FEZF1-AS1 promoted chemoresistance, autophagy and epithelial-mesenchymal transition (EMT) through regulation of miR-25-3p/ITGB8 axis in PC, providing a new regulatory mechanism of PC and a novel therapeutic target. |
| Pubmed ID | 32196579 |
| Year | 2020 |
| Title | LncRNA FEZF1-AS1 Promoted Chemoresistance, Autophagy and Epithelial-Mesenchymal Transition (EMT) Through Regulation of miR-25-3p/ITGB8 Axis in Prostate Cancer |
External Links
| Links for FEZF1-AS1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |